Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, and Ipsen (Euronext: FR0010259150; IPN), an innovation-driven global specialty pharmaceutical Group, announced that the 6-month sustained-release formulation of Decapeptyl®1 (triptorelin embonate2 22.5 mg) successfully completed its European decentralised registration procedure involving nine countries: Germany (reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain and The Netherlands.

13 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada

Depomed, Inc. announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an investigational non-hormonal extended release formulation of gabapentin for the treatment of menopausal hot flashes.

12 Oct 2009

Kimberly-Clark to acquire I-Flow Corporation

Kimberly-Clark Corporation and I-Flow Corporation, a leading healthcare company that develops and markets technically advanced, low-cost drug delivery systems and innovative products for post-surgical pain relief and surgical site care, today announced a definitive agreement whereby I-Flow will be acquired in a cash tender offer for approximately $324 million on a fully diluted basis.

9 Oct 2009

Clemson bioengineer designing new ways to target drugs

Clemson bioengineer Frank Alexis is designing new ways to target drugs and reduce the chances for side effects.

9 Oct 2009

Emisphere Technologies announces commercial launch of oral Eligen B12

Emisphere Technologies, Inc. today announced that the Company is introducing and launching its first commercially available product, oral Eligen® B12 (100 mcg). Oral Eligen® B12 (100 mcg) has been specifically developed to help improve Vitamin B12 absorption and bioavailability with a patented formulation.

8 Oct 2009

BioDelivery Sciences' partner Meda to launch ONSOLIS for managing breakthrough pain

BioDelivery Sciences International, Inc. announced that its commercial partner Meda will launch the FDA-approved ONSOLIS (fentanyl buccal soluble film) next week for the management of breakthrough pain (BTP) in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.

8 Oct 2009

Halozyme Therapeutics to host a meeting for analysts and investors

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will host a meeting for analysts and investors on October 15 in New York.

8 Oct 2009

Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration

MacuCLEAR, Inc. and Mystic Pharmaceuticals, Inc., announced today preliminary successful results of a Phase Ib Clinical Trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD). The preliminary results indicated that MacuCLEAR’s MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina.

8 Oct 2009

3M Drug Delivery Systems expands operations, establishes new facility at Singapore

3M Drug Delivery Systems today announced the expansion of its capabilities with a new laboratory site at the 3M Singapore facility in Yishun. The Singapore lab will develop products in both the inhalation and transdermal drug delivery categories, bringing 3M’s innovative inhalers and patches to pharmaceutical customers and patients in the Asia Pacific region.

8 Oct 2009

Cipher Pharmaceuticals enrolls first patient in Phase III study of CIP-ISOTRETINOIN

Cipher Pharmaceuticals Inc. today announced that it has enrolled the first patient in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne.

7 Oct 2009

Roche and Genentech obtain license to use SurModics’ drug delivery system

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today that it has signed a License and Development Agreement with Roche and Genentech, Inc., a wholly-owned member of the Roche Group.

7 Oct 2009

Impax Laboratories settles FLOMAX litigation, to launch generic tamsulosin hydrochloride product

Impax Laboratories, Inc. today announced that it has reached agreement with Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. to settle pending U.S. litigation with regard to US Patent No. 4,703,063 for FLOMAX® (generic name: tamsulosin hydrochloride) capsules through the entry of a consent judgment confirming the validity and infringement of the patent. FLOMAX® is a treatment for the functional symptoms of benign prostatic hyperplasia.

7 Oct 2009

Vitro Diagnostics' research reveals expanded uses of its fluorescent stem cells

Vitro Diagnostics, Inc., dba Vitro Biopharma, announced completion of a research report concerning its fluorescent stem cells, http://www.vitrobiopharma.com/wp-content/uploads/2009/10/fluorescent-msc-10-3.pdf. This report revealed transfer of fluorescent to differentiated cells including chondrocytes, cells responsible for making cartilage.

7 Oct 2009

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

BioDelivery Sciences International, Inc. has received a $1.3 million grant from the Walter Reed Army Institute of Research for Bioral Amphotericin B, an oral formulation of the fungicidal treatment amphotericin B in BDSI’s patented Bioral drug delivery technology, to further study the formulation in the treatment of Cutaneous Leishmaniasis.

6 Oct 2009

iMedicor to market Access Pharmaceuticals' MuGard in North America

ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

6 Oct 2009

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

Transdel Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing topically administered products using its proprietary transdermal delivery platform, today announced positive top-line clinical results for its lead pain drug Ketotransdel®( )in a Phase 3 trial which evaluated the efficacy and safety of the drug in acute soft tissue injuries of the upper and lower extremities.

6 Oct 2009

NIMH awards SRI International a $6.3M contract for study of ligands for brain imaging research

SRI International, an independent nonprofit research and development organization, announced today that it has been awarded a $6.3 million contract by the National Institute of Mental Health (NIMH) to conduct preclinical safety studies of promising novel ligands that will be used for brain imaging research and clinical applications.

6 Oct 2009

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.

6 Oct 2009

DuraPrep solution effective against surgical-site infections

3M Health Care today announced the publication of a new independent study “Effects of Preoperative Skin Preparation on Postoperative Wound Infection Rates:

6 Oct 2009

Drug Delivery News and Research

Further Reading

Debiopharm Group and Ipsen complete European decentralised registration of Decapeptyl

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Depomed announces results from BREEZE 1 and 2 Phase 3 clinical trials of Serada

Kimberly-Clark to acquire I-Flow Corporation

Clemson bioengineer designing new ways to target drugs

Emisphere Technologies announces commercial launch of oral Eligen B12

BioDelivery Sciences' partner Meda to launch ONSOLIS for managing breakthrough pain

Halozyme Therapeutics to host a meeting for analysts and investors

Macuclear and Mystic announce groundbreaking results from Phase Ib Clinical Trial for Macular Degeneration

3M Drug Delivery Systems expands operations, establishes new facility at Singapore

Cipher Pharmaceuticals enrolls first patient in Phase III study of CIP-ISOTRETINOIN

Roche and Genentech obtain license to use SurModics’ drug delivery system

Impax Laboratories settles FLOMAX litigation, to launch generic tamsulosin hydrochloride product

Vitro Diagnostics' research reveals expanded uses of its fluorescent stem cells

US Army grants BioDelivery Sciences $1.3M for investigating Bioral Amphotericin B

iMedicor to market Access Pharmaceuticals' MuGard in North America

Phase 3 results of Transdel's lead topical pain drug Ketotransdel announced

NIMH awards SRI International a $6.3M contract for study of ligands for brain imaging research

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

DuraPrep solution effective against surgical-site infections

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News